Join to View Full Profile
300 Pasteur DrStanford, CA 94305
Phone+1 650-723-4000
Dr. Frank is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology and Medical Oncology, 2015 - 2018
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2011 - 2014
David Geffen School of Medicine at UCLAClass of 2011
Certifications & Licensure
CA State Medical License 2013 - 2026
MA State Medical License Active through 2013
Publications & Presentations
PubMed
- Donor regulatory T-cell therapy to prevent graft-versus-host disease.Everett H Meyer, Anna Pavlova, Alejandro Villar-Prados, Cameron Bader, Bryan Xie
Blood. 2025-05-01 - Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL.Yi-Jiun Su, Anne Marijn Kramer, Mark P Hamilton, Neha Agarwal, Hrishikesh K Srinagesh
Cancer Discovery. 2025-04-02 - Lisocabtagene Maraleucel for Richter's Transformation-A Case Series.Courtney J Smith, Anmol Goyal, Brian R Smith, Dasom Lee, Alexandria Jensen
Ejhaem. 2025-04-01
Abstracts/Posters
- Identification of Two CAR T-Cell Populations Associated with Complete Response or Progressive Disease in Adult Lymphoma Patients Treated with Axi-CelMatthew J. Frank, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)Matthew J. Frank, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase I/II Trial of Intratumoral CpG, Local Low-Dose Radiation, and Oral Ibrutinib in Patients with Low-Grade B-Cell LymphomaMatthew J. Frank, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Monitoring ctDNA in r/r DLBCL patients following the CAR T-cell therapy axicabtagene ciloleucel: Day 28 landmark analysis.ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
- Intratumoral Injection of CpG-ODN Plus Systemic Ibrutinib Induces an Anti-Tumor Immune Response Affecting T Cell Subsets in the Microenvironment of Both Injected and N...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Stanford Medicine’s Top Scientific Advancements of 2024December 13th, 2024- If CD19 CAR T Cell Therapy Fails in Lymphoma, Try a CD22 VersionJuly 11th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
